Latest Breaking News On - கீந் வெளிப்பாடு - Page 1 : comparemela.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for . ObsEva SAAugust 4, 2021 GMT - s - Published -   Geneva, Switzerland and Boston, MA – August 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the publication of two peer-reviewed papers on nolasiban, an oxytocin receptor antagonist in development for improving live birth rates in women undergoing embryo transfer following in-vitro fertilization (IVF). ADVERTISEMENT Human Reproduction. The study reports the results from a meta-analysis of three randomized, placebo-controlled trials showing that nolasiban increased the likelihood of live birth following IVF. Participants were administered a single oral dose of nolasiban 900 mg (n=846) or placebo (n=864) and

United statesShauna dillonPatientsacross threerandomizedGeorg griesingerPiotr pierzynskiJoyce allaireExchange commissionMerck kgaMerck kgaaSwiss exchangeLive birthinAcross threerandomizedPlacebo controlled clinical trialspublishedHuman reproductionBlood flowGene expression